

Nonlinear Fitness Consequences of Variation in Expression Level of a Eukaryotic Gene

Joshua S. Rest,^{*,1} Christopher M. Morales,¹ John B. Waldron,¹ Dana A. Opulente,¹ Julius Fisher,¹ Seungjae Moon,^{‡,1} Kevin Bullaughey,² Lucas B. Carey,³ and Demitri Dedousis¹

¹Department of Ecology and Evolution, Stony Brook University

²Department of Ecology and Evolution, University of Chicago

³Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel

[‡]Present address: Weill Cornell Graduate School of Medical Science, New York, NY 10065

*Corresponding author: E-mail: joshua.rest@stonybrook.edu.

Associate editor: Matthew Hahn

Abstract

Levels of gene expression show considerable variation in eukaryotes, but no fine-scale maps have been made of the fitness consequences of such variation in controlled genetic backgrounds and environments. To address this, we assayed fitness at many levels of up- and down-regulated expression of a single essential gene, *LCB2*, involved in sphingolipid synthesis in budding yeast *Saccharomyces cerevisiae*. Reduced *LCB2* expression rapidly decreases cellular fitness, yet increased expression has little effect. The wild-type expression level is therefore perched on the edge of a nonlinear fitness cliff. *LCB2* is upregulated when cells are exposed to osmotic stress; consistent with this, the entire fitness curve is shifted upward to higher expression under osmotic stress, illustrating the selective force behind gene regulation. Expression levels of *LCB2* are lower in wild yeast strains than in the experimental lab strain, suggesting that higher levels in the lab strain may be idiosyncratic. Reports indicate that the effect sizes of alleles contributing to variation in complex phenotypes differ among environments and genetic backgrounds; our results suggest that such differences may be explained as simple shifts in the position of nonlinear fitness curves.

Key words: sphingolipids, gene regulatory evolution, *Saccharomyces cerevisiae*, fitness function, gene expression.

Introduction

Some mutations have large effects on the fitness of organisms, whereas others have little or no effect on fitness (Fisher 1928; Wright 1929; Haldane 1930; Orr 1991; Deutschbauer et al. 2005). One explanation for this is that the impact of mutations on fitness (healthy growth and reproduction) is often not linearly affected by the amount that a mutation changes gene activity or expression. Although a linear relationship is often assumed, it has been demonstrated that allelic differences can have a nonlinear effect on fitness (Wright 1934; Hartl et al. 1985; Dykhuizen et al. 1987; Birchler et al. 2001; Veitia 2002; Papp et al. 2003). For example, either an increase or a decrease in the expression of a gene can create a stoichiometric imbalance among proteins in a complex, and thus either type of change may decrease fitness (Birchler et al. 2001; Veitia 2002; Papp et al. 2003). Another nonlinear fitness function describes the diminishing returns of increases in the effective activity of metabolic enzymes when alleles vary either in the protein sequence or expression level of the enzyme (Wright 1934; Hartl et al. 1985; Dykhuizen et al. 1987). Gene expression is a phenotype that shows extensive natural variation, and comparative analyses suggest that much of this variation has little physiological effect (Khaitovich et al. 2005; Yanai and Hunter 2009). The shape of the expression–fitness curve for a gene is a tool for more directly determining the causes and consequences of such variation within a species.

The shape of expression–fitness curves for *lac* genes has been studied in bacteria, and the resulting curves are nonlinear and change in different environments (Dekel and Alon 2005; Perfeito et al. 2011). Expression–fitness curves for eukaryotic genes could similarly yield insight into the distribution of the consequences of mutations. However, no published studies have characterized fitness as a function of gene expression at high resolution in eukaryotes (Bayer 2010), which would permit a more powerful test of the hypothesis that genetic variation has a nonlinear effect on fitness.

As a first step toward this goal, we chose to quantitatively measure the expression–fitness curve, in *Saccharomyces cerevisiae*, of the essential and conserved metabolic gene, *LCB2*, which encodes a key enzyme in the sphingolipid synthesis pathway (fig. 1). This pathway synthesizes and manages a spectrum of functionally diverse products and metabolites with key structural and signaling roles that mediate responses to changing physiologic and environmental cues (Hannun and Obeid 2008). Sphingolipids are essential components of the plasma membrane, and are involved in processes including signaling, proteolysis, cytoskeletal changes, nutrient uptake, regulation of cell growth, and stress response (Nagiec et al. 1994; Cowart and Obeid 2007). *Lcb2* binds in stoichiometric complex with *Lcb1* to form serine palmitoyltransferase (SPT), which catalyzes the first committed step in sphingolipid synthesis (fig. 1) (Gable et al. 2002). Misregulation of sphingolipids has been shown to cause

© The Author(s) 2012. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Open Access




Fig. 1. The cellular sphingolipid synthesis pathway and corresponding responses to changes in *LCB2* expression. On left, the sphingolipid biosynthesis pathway in *Saccharomyces cerevisiae* is shown. *Lcb2*, the product of the titrated gene *LCB2*, catalyzes the first committed step in this pathway. Sphingolipid compounds were measured in response to changing levels of *LCB2*, and sphingolipids that displayed a significant response are shown to the right of their corresponding step in the pathway. All comparisons shown between sphingolipid levels in cells with wild-type *LCB2* expression and with reduced (−2.7-fold) expression are significant according to a two tailed t test at a *P* value less than 0.05. Bars indicate medians and standard errors of nine biological replicates. Means, standard errors, and *P* values for all measured sphingolipid compounds at three *LCB2* levels are provided in supplementary table S1, Supplementary Material online.

disruptions in their key structural and signaling roles and to have severe consequences for the cell (Hannun and Obeid 2008). The role of *LCB2* in sphingolipid synthesis makes it an intriguing gene for studying the effects of variation in gene expression on cellular fitness. Importantly, sphingolipids and their diverse downstream products can be measured, and thereby give an additional quantitative phenotype between gene expression and fitness. In addition, *LCB2* is a good choice for studying expression–fitness curves, because 1) it exhibits stoichiometric binding, such that dosage balance may affect fitness (Gable et al. 2002), 2) it shows variation in expression patterns among ecologically divergent yeast strains (Rossouw et al. 2009; Eng et al. 2010), which can shed light on the shape of the fitness curve, and 3) it is already known to affect cell growth, resulting in a severe growth defect when repressed (Mnaimneh et al. 2004). For experimental reasons, *LCB2* is an appropriate candidate because it is not cell cycle regulated (Spellman et al. 1998), not periodically expressed during metabolic bursts (Tu et al. 2005), not dynamically expressed over the course of fermentative growth (Rossouw et al. 2009), and does not show cell-to-cell variation in expression (Newman et al. 2006). Therefore, we expect that any phenotypic consequences of changes in expression will be due to the level of expression, and not changes in the temporal dynamics of expression.

One of the challenges in assessing the fitness consequences of variation in level of gene expression is identifying a genetic system in which gene expression can be experimentally manipulated and its fitness consequences measured. One possible approach would be to mutate a gene's promoter, but this is difficult to achieve because most promoter mutations either have no effect or lead to a coarse-grained decrease in expression (Patwardhan et al. 2009). To solve this problem, we used a chemically titratable promoter system that does not directly affect fitness to create a range of expression

phenotypes for a single gene (Hughes et al. 2000; Peng et al. 2003; Mnaimneh et al. 2004). We mimicked graded allelic variation in gene expression level using the strain *TetO₇-LCB2*, in which the native promoter of the gene *LCB2* has been replaced with a doxycycline-regulated promoter (Tet-Off system) (Mnaimneh et al. 2004). We find that this titratable promoter system is an excellent tool for exploring expression–fitness curves and how they are affected by changing environments and genetic backgrounds.

Results

Fitness and Sphingolipid Flux Consequences of Variation in *LCB2* Expression

We first determined the dose-response curve between doxycycline concentration and *LCB2* expression in *TetO₇-LCB2* (fig. 2A). Using this expression–titration function, we measured fitness at 29 expression levels under head-to-head competition in mixed culture with a fluorescent reference strain (fig. 2C). We defined fitness as the rate of cell growth and division in batch culture relative to the wild-type (parental strain R1158).

As expression was reduced from the wild-type level in standard media, fitness rapidly decreased, dropping 19% in conjunction with a 2-fold (50%) drop in *LCB2* expression (solid red curve in fig. 2C). This represents a dramatic fitness cost—such alleles would very quickly be removed from wild populations by natural selection. Our high-resolution data reveal that the wild-type expression level is located directly at the edge of this fitness cliff, so that even a small decrease in expression has a large fitness cost. In contrast, overexpression of *LCB2* up to a level 7.3-fold greater than wild-type did not markedly change fitness. The fact that the slope of the fitness curve is steep in response to decreases in *LCB2* expression but flat in response to increases in expression indicates that




Fig. 2. Titrated levels of gene expression reveal a fitness cliff for the gene *LCB2* in *Saccharomyces cerevisiae* strain *TetO₇-LCB2*. We measured the relationship between doxycycline concentration and *LCB2* expression level in (A) standard media and (B) osmotic stress media. Expression levels were determined by qPCR, and each curve was fitted with a five-parameter log-logistic regression. Box and whisker plots (gray bars and dashed lines) indicate error estimates for qPCR measurements from at least three biological replicates, and capped solid lines indicate error estimates based on a regression model. (C) We assessed cellular fitness relative to levels of *LCB2* expression for *TetO₇-LCB2* grown in two environments. The sharp fitness cost for decreases in *LCB2* expression shows that the wild-type level of expression is on the edge of a fitness cliff. The shape of the fitness function in osmotic stress media (dashed line) is similar to its shape in standard media (solid line), although shifted toward higher levels of *LCB2* expression in the former. Gene expression is relative to the level of expression in the parental wild-type (R1158) in standard media; arrows indicate wild-type expression levels in each environment. Fitness is normalized to the wild-type equivalent in each environment. Semitransparent boxes indicate error boundaries for fitness (standard error of at least three, and on average five, biological replicates) and for expression estimates (regression model-based error).

changes in *LCB2* expression have highly nonlinear fitness consequences.

We expected that changes in *LCB2* gene expression would affect sphingolipid levels because of its key position at the head of the sphingolipid synthesis pathway (fig. 1). We

quantitated several of the earliest sphingolipid metabolites in the de novo synthesis pathway, including dihydrosphingosine and 20 species of ceramides, which are intermediates in the formation of complex sphingolipids. In cells with a 7.3-fold increase in *LCB2* expression, we did not observe changes in

any sphingolipids measured (supplementary table S1, Supplementary Material online), consistent with the lack of an obvious fitness consequence (fig. 2C). However, the decrease in fitness we observed when we titrated *LCB2* expression 2.7-fold (63%) below wild type was associated with changes in the levels of several ceramides. Specifically, we observed a significant decrease in the level of C18:1 dihydroceramide (two-tailed *t* test, $P = 0.022$; fig. 1), whereas four other ceramide species increased [two-tailed *t* test: C18 ($P = 0.037$), C20 ($P = 0.044$), and C22:1 dihydroceramide ($P = 0.011$), C20:1 ceramide ($P = 0.038$)]. Individual ceramide species influence key aspects of longevity, including cell growth, regulation, differentiation, and death (reviewed in Hannun and Obeid 2011). We saw both decreases and increases in stearyl (C18) ceramides, which have an 18 carbon fatty acid in the ceramide or dihydroceramide moiety. Effects of stearyl ceramides on cell growth have been observed elsewhere, for example, they are involved in the progression of squamous cell carcinomas in human head and neck tumors (Koybasi et al. 2004).

Reduction in *LCB2* levels from wild-type also results in the altered transcription of many genes. According to data collected by Mnaimneh et al. (2004), a 3.8-fold (74%) reduction in *LCB2* expression results in a severe growth defect and with genome-wide transcriptional changes including repression of structural ribosomal genes and induction of genes associated with cellular stress response (supplementary table S2, Supplementary Material online).

The Fitness Curve Shifts in Response to Altered Environmental Conditions

The levels and types of sphingolipids required by a cell change across different environments, for example, in response to osmotic stress (Patton et al. 1992; Hannun and Obeid 2008), and we predicted that effect of varying *LCB2* levels would therefore also change among such environments. To determine the extent to which environmental change affects the *LCB2* expression–fitness curve, we measured the curve when the cells were subjected to osmotic stress. We noted that in the wild-type parental strain (R1158), *LCB2* expression was upregulated 1.6-fold in osmotic stress media compared with standard media (arrows in fig. 2C; fig. 3; two-tailed *t* test, $P = 0.004$). We first determined the dose–response function for the *TetO₇–LCB2* strain in osmotic stress media (fig. 2B). We then measured how changes in *LCB2* expression affected fitness in osmotic stress media. As expression increased 7.3-fold, there was no consistent change in fitness (dashed blue line in fig. 2C). As expression decreased 2.2-fold, there was a 12.6% reduction in fitness. Interestingly, the expression–fitness curve under osmotic stress is similar in shape to the curve in standard media but shifted to a region of higher expression. This shift in the fitness curve indicates the extent of selection for environment-specific responses in gene regulation.

Evidence for Distinct Fitness Curves in Different Genetic Backgrounds

The shape of the fitness curve indicates the relative fitness cost of mutant alleles compared with the wild-type and

accordingly predicts the expected levels of standing allelic variation in populations (Eanes 2011). Because low-expression alleles would have pronounced negative fitness consequences (fig. 2C), we would expect them to be rapidly purged from populations by natural selection. By the same token, high-expression alleles have no measurable fitness consequence and we would expect such alleles to segregate freely in populations. To test this hypothesis, we measured expression levels of *LCB2* in three ecologically and genetically divergent strains of *S. cerevisiae*: vineyard strain RM11-1a, pathogenic strain YJM145-a, and oak strain YPS 3332. Contrary to what the *LCB2* fitness curve led us to expect, two wild strains had significantly lower levels of *LCB2* expression than the lab strain both in standard media and in osmotic stress media (fig. 3). The level of *LCB2* expression was 1.5-fold (33%) lower in the pathogenic strain YJM145 and 1.4-fold (27%) lower in the vineyard strain RM11-1a than in the lab strain when both were grown in standard media (two-tailed *t* test, $P = 0.028$ and $P = 0.047$, respectively). This among-strain analysis requires that the reference gene we used for quantitative polymerase chain reaction (qPCR), *ALG9*, has not changed, as has been shown in previous studies across a variety of growth conditions and genetic backgrounds (Kvitek et al. 2008; Teste et al. 2009). We also checked our results using another stable qPCR reference gene according to these studies, *TFC1*, and found that YJM145 still had significantly different (1.5-fold lower) expression in comparison with the lab strain (two-tailed *t* test, $P = 0.009$).

If the fitness curves for *LCB2* expression were the same in YJM145 and RM11-1a as in the lab strain, the wild strains would presumably have lower fitness. A more likely interpretation is that the *LCB2* fitness curve itself has shifted in the lab strain due to epistasis with the genetic background and/or selection on sphingolipid levels. To the extent that different strains exhibit different expression–fitness curves, the level of permissible expression variation will be correspondingly affected. We hypothesize that there has been selection for higher levels of *LCB2* expression in the lab strain. Given that sphingolipids are involved in amino acid sensing and transport (Dickson 2010), one very plausible cause for this shift may have been the deletion in the lab strain of four genes that are involved in amino acid synthesis (Brachmann et al. 1998).

Expression Responses of Stoichiometric Interactors

To perform its function, *Lcb2* binds in a stoichiometric complex with *Lcb1* to form SPT (fig. 1). In turn, SPT is regulated through stoichiometric interactions with a repressor complex (*Orm1/2*) and an activator (*Tsc3*) (Monaghan et al. 2002; Breslow et al. 2010). It is important to consider *LCB1* expression when studying variation in *LCB2* expression, because the extent to which the subunits are coregulated or one subunit is limiting determines the level of functional SPT complex. To investigate this, we measured levels of *LCB1* in the lab and wild strains in both standard media and osmotic stress media. We found that *LCB2* and *LCB1* covary with each other across the strains and environments, consistent with




Fig. 3. *LCB2* and *LCB1* gene expression levels covary among wild strains of *Saccharomyces cerevisiae* and between growth environments. *LCB2* gene expression is upregulated in osmotic stress media (blue points) in comparison with levels of expression in standard media (orange points). *LCB2* levels are significantly lower in wild strains YJM145 and RM11-1a than in the auxotrophic lab strain R1158, suggesting that the expression–fitness function has evolved in the lab strain (asterisk; two-tailed *t* test, $P = 0.028$ and $P = 0.047$, respectively). Fold change was ascertained by qPCR and is relative to the expression level of the same gene in the lab strain (R1158) when grown in standard media. Standard errors of three or more biological replicates are shown.

this stoichiometric expectation (linear regression model, $P = 0.005$; fig. 3).

Discussion

The position of wild-type *LCB2* gene expression at the edge of a fitness cliff, where the slope rapidly changes, supports the hypothesis that the effects of mutations can be highly nonlinear. It is important to know how variation in a simple trait, such as gene expression, may affect more complex outcomes, such as disease or fitness. If complex outcomes respond linearly to trait variation, then the contribution of variation in many simple traits (e.g., from many loci) to complex outcomes may be easily calculated and inferred (e.g., in genetic association studies). Early work in bacteria suggested that linearity might prevail (Elena and Lenski 1997). However, the lack of success in genome-wide association studies in humans and its associated missing heritability have suggested that the picture may instead be much more complicated (Manolio et al. 2009). Other work has indicated that the quantitative contributions of loci to complex-trait variation may change completely in different combinations of environments and genetic backgrounds (Gerke et al. 2010). Indeed, we found here that for *LCB2* the effects of genetic variation are nonlinear and differ across environments and genetic backgrounds (Dekel and Alon 2005; Perfeito et al. 2011). Yet our continuous fitness curve (fig. 2C) also shows that missing information regarding the genetic basis of variation

in complex phenotypes (Manolio et al. 2009) is not an enigma but is instead consistent with fundamental theory about the rugged landscape of outcomes that results when nonlinear outcomes from many loci recombine in a population (Wright 1932). For nonlinear curves, predicting the effects of mutation *ab initio* is difficult, because the magnitude of the effect depends on the specific region of the fitness curve traversed by the mutation. In particular, it is challenging to distinguish between neutral and functional variation. However, by mapping fitness curves, the results of variation in different environments and genetic backgrounds can indeed be predicted. Titration of expression alleles in different environments (as demonstrated here) and in different genetic backgrounds holds great utility for interpreting variation in expression among cells, tissues, individuals, and populations.

We observed that any decreases in the expression level of *LCB2* from wild-type has a striking fitness cost (fig. 2C). Consistent with this, *LCB2* has low cell-to-cell variation in gene expression (Newman et al. 2006), as one might expect for a gene perched on a fitness cliff, where any variation that results in an expression decrease would be harmful. A large cost for relatively small *LCB2* dosage reductions makes sense, considering that sphingolipids require precise regulation (Hannun and Obeid 2008; Lebman and Spiegel 2008). This precise regulation of SPT (*Lcb1/Lcb2*) activity is achieved not by transcriptional responses but by direct interaction with a repressor, *Orm1/2* (fig. 1) (Breslow et al. 2010). The *Orm1/2* complex is phosphorylated in response to low levels of cellular sphingolipids, which diminishes the ability of the complex to oligomerize with and inhibit SPT; the resulting increase in SPT activity yields increased sphingolipid flux. Reduced *LCB2* expression leads to changes in flux through the sphingolipid pathway and to altered levels of essential ceramides (fig. 1); reduced *LCB2* expression therefore phenocopies *Orm* overexpression (Breslow et al. 2010). Sensitivity to decreased *LCB2* expression is consistent with the hypothesis that even small changes in the regulation of sphingolipids in humans can cause diseases such as childhood asthma, Crohn's disease, type 1 diabetes, and biliary cirrhosis. We found that *LCB2* expression is on the edge of a fitness cliff, consistent with SPT having a very high level of metabolic control. Sensitivity to variation in SPT activity may be due in part to its position near the head of the sphingolipid synthesis pathway (fig. 1), where variation has been suggested to exert the strongest control (Eanes 1999; Wright and Rausher 2010). However, we note that our result of a fitness cliff for reduction of *LCB2* in haploid yeast contrasts with the lack of a significant fitness cost for the hemizygous deletion of *LCB2* in diploids (Deutschbauer et al. 2005). Determining whether this discrepancy is due to different effects of *LCB2* reduction among haploids and diploids, or because of differences in growth conditions between our fitness assay (batch growth) and the hemizygous fitness assay (exponential growth) will require additional experimental work.

Why is overexpression of *LCB2* close to neutral with respect to fitness (fig. 2C)? Increases in *LCB2* transcription do not necessarily mediate a proportional increase in *Lcb2* protein levels. In particular, *Lcb2* is unstable unless it is associated

with Lcb1 (Gable et al. 2000; Yasuda et al. 2003), so if *LCB1* expression does not increase along with *LCB2*, any excess Lcb2 would be degraded. However, *LCB1* levels appear to be upregulated in response to upregulation of *LCB2* (fig. 3), and it is therefore unlikely that Lcb1 limitation is the sole factor underlying the absence of a fitness effect. Even if additional SPT is formed, this increased dose may not affect sphingolipid flux and fitness if there is enough Orm1/2 to inhibit SPT activity. Because wild-type levels of Lcb1 and Lcb2 are high enough that sphingolipid flux levels are toxic in the absence of Orm1/2 repression (Breslow et al. 2010), our findings suggest that Orm1/2 may be capable of buffering the cell against SPT levels that are greater than those found in wild-type.

It would seem advantageous, therefore, for the wild-type expression to fall within the region of high expression that offers a buffer from the genetic, environmental, or stochastic perturbations that may lower *LCB2* levels. In other words, if the *LCB2* expression level were higher, then mutations that decrease *LCB2* expression would not result in severely compromised fitness. There are several possible explanations for the precarious position of wild-type expression of *LCB2* on the edge of this fitness cliff (fig. 2C). One possibility is that there are other growth environments in which there is a cost to overexpression (Hillenmeyer et al. 2008). A second possibility is that there is a small deleterious fitness consequence for expressing *LCB2* above wild-type levels that is beyond our measurement resolution. It has been estimated that an otherwise neutral 2-fold increase in gene expression will be selected against solely due to the metabolic costs of mRNA and protein production, for all genes except those with the lowest levels of expression (Wagner 2005, 2007). The critical selection coefficient in *Saccharomyces*, above which selection on an allele will predominate over drift, has been calculated to be very small ($\sim 2.93 \times 10^{-7}$) based on estimates of mutation rate and of a large historical population size (Wagner 2005). This is well below the resolution of our fitness measurements, so the fitness curve in figure 2C may indeed have a peak at the wild-type expression level, albeit with a shallow slope on the right-hand side. It is also possible that there is no accessible mutational path for the *LCB2* promoter to achieve higher expression, or that the mutational target for *LCB2* regulation is much larger than expected, and drift thus predominates (i.e., the critical selection coefficient is higher than estimated). The position on the edge of a cliff may also permit sphingolipid synthesis to be very rapidly reduced in environments where cell longevity is more important than rapid growth (Huang et al. 2012). An additional possibility, we propose, is that the lab strain has recently experienced strong selection for increased *LCB2* expression associated with the loss of amino acid synthesis pathways, and given enough time, the expression level may evolve away from its precipitous position at the edge of the fitness cliff.

The cliff-like shape of the *LCB2* expression–fitness curve mirrors the shape observed by varying expression levels in a model of the mitogen-activated protein kinase (MAPK) signaling cascade developed by Nijhout et al. (2003). The phenotypic output in their system is the level of active MAPK, and

they examine the effect of varying expression and activity at each level of the cascade. In particular, at the highest two levels of the cascade (MAPKKK and MAPKK), the effect of variation is large at low expression levels but saturates at higher expression levels, as we observe with *LCB2*. The authors point out that wild-type model parameters, such as expression level, are typically unknown. However, they suggest that wild-type phenotypes are unlikely to occur deep within plateaus of a fitness curve or where the fitness curve is steeply sloped. Instead, they conclude that it is most likely that wild-type phenotypes will lie near the edges of fitness curves, as we observe here for *LCB2*.

Although our fitness curve measured in the lab is real, it is unclear if it reflects aspects of fitness that are important in the wild. Yeast grows exponentially when in glucose, but growth slows as glucose is used up and the population saturates, and we serially diluted the culture into fresh media every 24 h so that growth could continue. As each culture went through several cycles of lag phase, exponential growth, and saturation, our fitness measurements include both absolute growth rate and other factors such as recovery and exit from lag phase. However, it is likely that the effect of *LCB2* expression on relative fitness would differ among growth conditions. For example, other components of fitness that have been investigated are sporulation efficiency in the wild (Gerke et al. 2006), exponential growth in chemostats (Dykhuizen and Hartl 1983), and long-term survival under nutrient limited conditions (Gresham et al. 2008).

The laboratory adapted strain S288C, from which *TetO₇–LCB2* is derived, has experienced recurrent bottlenecks and therefore shows high evolutionary rates (Gu et al. 2005). This mosaic strain lacks a key gene for flocculation (Liu et al. 1996), and *TetO₇–LCB2* lacks genes required for synthesis of three amino acids. Consistent with this history of bottlenecks, genetic manipulation, and elevated rates of evolution, S288C and its derivatives are outliers among *S. cerevisiae* for a variety of phenotypes including growth on ethanol and maltose (Warringer et al. 2011) and sporulation efficiency (Deutschbauer and Davis 2005). It is possible that our observation of *LCB2* wild-type expression at the edge of a fitness cliff could similarly be an outlier. It will be important in future work to measure the *LCB2* expression–fitness curves in wild strains to determine whether their wild-type expression levels are similarly positioned.

LCB2 is an essential gene with a relatively low expression level, and these factors likely contribute to the steepness of its fitness curve as expression decreases. Previous work indicates that the consequences of decreased expression for essential genes are distributed similarly to nonessential genes (Delneri et al. 2008). However, there is substantial heterogeneity among all genes in the phenotypic and fitness effects of both overexpression (Sopko et al. 2006) and reduced expression (Giaever et al. 2002; Mnaimneh et al. 2004; Deutschbauer et al. 2005; Delneri et al. 2008). There are likely to be many different shapes of expression–fitness curves, reflecting the proteome's diversity of functions and structures and the complex web of interactions among genes and proteins.

These caveats highlight the need to expand this work to a panel of wild-strains, as well as to additional genes and environments. We expect there will be multiple classes of expression–fitness curves, and we foresee that such systematic investigations will begin to quantitatively describe how standing variation results from the evolutionary integration over environment and genetic-background specific fitness curves. Systems like the Tet-Off promoter, as we use here, allow genes to be systematically titrated, and the physiological and fitness consequences quantitatively examined. Our results show that such systems hold the possibility for producing larger scale catalogs of expression–fitness curves that would serve as a tool for interpreting natural variation in gene expression levels.

Materials and Methods

Titration of LCB2 Expression

We altered levels of LCB2 expression in *S. cerevisiae* strain *TetO₇–LCB2* (*pLCB2::kanR–TetO₇–TATA URA3::CMV–tTA MATa his3-1 leu2-0 met15-0*), in which the native LCB2 promoter has been replaced by a tetracycline/doxycycline repressible promoter, *TetO₇* (Mnaimneh et al. 2004). LCB2 mRNA levels were measured at as many as 29 different concentrations of doxycycline, depending on the growth condition.

Fitness Competitions

Fitness at each level of doxycycline was measured via head-to-head competition between *TetO₇–LCB2* and a fluorescent reference strain, *GPM1–GFP* (Huh et al. 2003). Our growth protocol was as follows: *TetO₇–LCB2* and reference cells were grown separately in liquid media for 24 h, diluted to a density of 1.5×10^7 cells/mL, and then grown for ~8 additional hours. The two strains were then mixed in 10:1 (*TetO₇–LCB2*: reference) ratios and 8×10^6 cells were inoculated into 150 μ L of media at the appropriate concentration of doxycycline hyclate (Calbiochem). Additional wells contained pure cultures of the reference strain or the parental strain (R1158; *URA3::CMV–tTA MATa his3-1 leu2-0 met15-0*). Cultures were grown in triplicate in black-wall, clear-bottom 96-well plates (Nunc) covered with foil seals (Corning) and shaken at 1,300 rpm (DTS4, Elmi) at 30°C. The standard growth environment was synthetic defined media without tryptophan (SD–Trp, Sunrise Scientific). The osmotic stress environment contained 0.3 M (instead of 0.1 M) NaCl. Competitions were diluted 1:50 into fresh media every 24 h for 4 days. The optical density *A* (OD units at 600 nm) and raw fluorescence *B* (485 nm excitation, 530 nm emission) of each microwell culture were recorded hourly (F500, Tecan). We calculated *F*, fluorescence per unit OD:

$$F = \frac{B}{A} \quad (1)$$

where one unit OD contains 7.39×10^7 cells/mL. Relative fitness, ω , of *TetO₇–LCB2* in each doxycycline concentration, *C*, and environment, *E*, was derived from the rate of change over 4 days in the proportion of *TetO₇–LCB2* to the reference

strain in the competition culture, as measured by changes in $F_{\text{competition}}$, the fluorescence per unit OD of the competition culture:

$$\omega_{C,E} = 1 - \log_2(d) \times \frac{\Delta \ln \left(\frac{F_{\text{competition}_{C,E}} - F_{\text{parental}_{C,E}}}{F_{\text{referenceonly}_{C,E}} - F_{\text{competition}_{C,E}}} \right)}{\Delta t} \quad (2)$$

where *d* is the dilution factor (1:50) per unit time *t* (1,440 min), and F_{parental} and $F_{\text{referenceonly}}$ are the fluorescence per unit OD of parental cells only or reference cells only, respectively. We only used *F* when *A* fell between 0.57 and 0.70 (equivalent to 4.2×10^7 and 5.2×10^7 cells/ml), which allowed us to compare data among wells and days that fell in a similar optical range. Each doxycycline concentration and environment combination had, on average, five biological replicates on unique plates and days.

Measurement of LCB2 and LCB1 mRNA Levels

TetO₇–LCB2 was grown to measure levels of LCB2 expression at different concentrations of doxycycline in each environment. All growth conditions were identical to the competition protocol (e.g., in microwell plates), except that *TetO₇–LCB2* was grown in monoculture. Subset of samples was grown both in test tubes and in microwell plates. In addition, LCB2 expression in each environment was assayed for the parental strain (R1158) and for oak (YPS 3332; *MATa ho::Nat*) (Murphy et al. 2006), vineyard (RM11-1a; *MATa leu2Δ ura3Δ ho::Kan*) (Brem et al. 2002), and pathogenic (YJM145a; *MATa gal2 HO*) (McCusker et al. 1994) wild strains. Growth of each treatment and strain combination was repeated at least three times on unique days and plates. RNA was extracted on the second day of growth once cultures reached an optical density of 0.6 ($\sim 4.4 \times 10^7$ cells/ml; Zymolyase, Spin Columns, Zymo Research; Turbo DNA-free, Ambion). Expression levels were quantified using quantitative reverse transcriptase-PCR with the LCB2 primers 5′-TTGCTGTGTTGTTGTTGCTTATCCTGCT-3′ and 5′-CGTCGTAAGTGGATTTGCCGGAATTTGAT-3′ and LCB1 primers 5′-GCACACA TCCCAGAGGTTTT-3′ and 5′-TGTCCTGTATGGATCGT CA-3′ (Brilliant II SYBR 1-Step, Agilent; Mx3000P, Stratagene). *ALG9* served as a reference gene for normalization of the qPCR reactions, with primers 5′-CACGGATAGTGGCTTTGG TGAACAATTAC-3′ and 5′-TATGATTATCTGGCAGCAGGAA AGAACTTGGG-3′. We normalized a subsample of reactions with an additional reference gene, *TFC1*, with primers: 5′-GCT GGCATCATATCTTATCGTTTCACAATGG-3′ and 5′-GAAC CTGCTGTCAATACCGCTGGAG-3′. None of the primer sets (LCB2, *ALG9*, and *TFC1*) contained mismatches to their cognate sequences in the wild strains analyzed. Each qPCR reaction was repeated at least three times on separate plates. qPCR data were analyzed according to the $2^{-\Delta\Delta Ct}$ method (Livak and Schmittgen 2001). For each environment, we fitted the relationship between doxycycline concentration and fold change with a five-parameter log-logistic function and

used the function to predict final values and estimate error (R v2.14; package drc v2.2-1).

Sphingolipid Analysis

Sphingolipid metabolites at critical points in the sphingolipid synthesis pathway were extracted from monocultures of *TetO₇-LCB2* grown under conditions identical to those for qPCR. Nine biological replicate cultures were grown, each at three concentrations of doxycycline: 0, 0.0293, and 2.5 µg/ml, equivalent to 7.3-fold higher, the same as, and 2.7-fold lower than wild type expression, respectively. Sphingolipid levels were quantitated using LC-MS/MS by the lipidomics core facility at Medical University of South Carolina, following methods that are described in Bielawski et al. (2006).

Supplementary Material

Supplementary tables S1 and S2 are available at *Molecular Biology and Evolution* online (<http://www.mbe.oxfordjournals.org/>).

Acknowledgments

The authors thank Walter Eanes, Geoffrey Morris, Aman Gill, Niamh O'Hara, Bin He, Jeffrey Rest; two anonymous reviewers for comments on the manuscript; and Jason O'Rawe, Geoff Bolen, and Laura Praissman for assistance in the lab. Paul Sniegowski provided strain YPS 3332. This work was supported by startup funds from Stony Brook University to J.S.R.

References

- Bayer TS. 2010. Using synthetic biology to understand the evolution of gene expression. *Curr Biol*. 20:R772–R779.
- Bielawski J, Szulc ZM, Hannun YA, Bielawska A. 2006. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. *Methods* 39: 82–91.
- Birchler JA, Bhadra U, Bhadra MP, Auger DL. 2001. Dosage-dependent gene regulation in multicellular eukaryotes: implications for dosage compensation, aneuploid syndromes, and quantitative traits. *Dev Biol*. 234:275–288.
- Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, Hieter P, Boeke JD. 1998. Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. *Yeast* 14:115–132.
- Brem RB, Yvert GJ, Clinton R, Kruglyak L. 2002. Genetic dissection of transcriptional regulation in budding yeast. *Science* 296:752–755.
- Breslow DK, Collins SR, Bodenmiller B, Aebersold R, Simons K, Shevchenko A, Ejsing CS, Weissman JS. 2010. Orm family proteins mediate sphingolipid homeostasis. *Nature* 463:1048–1053.
- Cowart LA, Obeid LM. 2007. Yeast sphingolipids: recent developments in understanding biosynthesis, regulation, and function. *Biochim Biophys Acta*. 1771:421–431.
- Dekel E, Alon U. 2005. Optimality and evolutionary tuning of the expression level of a protein. *Nature* 436:588–592.
- Delneri D, Hoyle DC, Gkargkas K, et al. (12 co-authors). 2008. Identification and characterization of high-flux-control genes of yeast through competition analyses in continuous cultures. *Nat Genet*. 40:113–117.
- Deutschbauer AM, Davis RW. 2005. Quantitative trait loci mapped to single-nucleotide resolution in yeast. *Nat Genet*. 37:1333–1340.
- Deutschbauer AM, Jaramillo DF, Proctor M, Kumm J, Hillenmeyer ME, Davis RW, Nislow C, Giaever G. 2005. Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast. *Genetics* 169: 1915–1925.
- Dickson RC. 2010. Roles for sphingolipids in *Saccharomyces cerevisiae*. In: Chalfant C, Del Poeta M, editors. Sphingolipids as signaling and regulatory molecules. New York: Springer. p. 217–231.
- Dykhuizen DE, Dean AM, Hartl DL. 1987. Metabolic flux and fitness. *Genetics* 115:25–31.
- Dykhuizen DE, Hartl DL. 1983. Selection in chemostats. *Microbiol Rev*. 47: 150.
- Eanes WF. 1999. Analysis of selection on enzyme polymorphisms. *Annu Rev Ecol Syst*. 30:301–326.
- Eanes WF. 2011. Molecular population genetics and selection in the glycolytic pathway. *J Exp Biol*. 214:165–171.
- Elena SF, Lenski RE. 1997. Test of synergistic interactions among deleterious mutations in bacteria. *Nature* 390:395–398.
- Eng KH, Kvittek DJ, Keleş S, Gasch AP. 2010. Transient genotype-by-environment interactions following environmental shock provide a source of expression variation for essential genes. *Genetics* 184:587–593.
- Fisher RA. 1928. The possible modification of the response of the wild type to recurrent mutations. *Am Nat*. 62:115–126.
- Gable K, Han G, Monaghan E, Bacikova D, Natarajan M, Williams R, Dunn TM. 2002. Mutations in the yeast *LCB1* and *LCB2* genes, including those corresponding to the hereditary sensory neuropathy type I mutations, dominantly inactivate serine palmitoyltransferase. *J Biol Chem*. 277:10194–10200.
- Gable K, Slife H, Bacikova D, Monaghan E, Dunn TM. 2000. Tsc3p is an 80-amino acid protein associated with serine palmitoyltransferase and required for optimal enzyme activity. *J Biol Chem*. 275: 7597–7603.
- Gerke J, Lorenz K, Ramnarine S, Cohen B. 2010. Gene-environment interactions at nucleotide resolution. *PLoS Genet*. 6: e1001144.
- Gerke JP, Chen CTL, Cohen BA. 2006. Natural isolates of *Saccharomyces cerevisiae* display complex genetic variation in sporulation efficiency. *Genetics* 174:985.
- Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, Dow S, Lucau-Danila A, Anderson K, Andre B. 2002. Functional profiling of the *Saccharomyces cerevisiae* genome. *Nature* 418:387–391.
- Gresham D, Desai MM, Tucker CM, Jenq HT, Pai DA, Ward A, DeSevo CG, Botstein D, Dunham MJ. 2008. The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast. *PLoS Genet*. 4:e1000303.
- Gu Z, David L, Petrov D, Jones T, Davis RW, Steinmetz LM. 2005. Elevated evolutionary rates in the laboratory strain of *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A*. 102:1092–1097.
- Haldane JBS. 1930. A note on Fisher's theory of the origin of dominance, and on a correlation between dominance and linkage. *Am Nat*. 64: 87–90.
- Hannun YA, Obeid LM. 2008. Principles of bioactive lipid signaling: lessons from sphingolipids. *Nat Rev Mol Cell Biol*. 9:139–150.
- Hannun YA, Obeid LM. 2011. Many ceramides. *J Biol Chem*. 286: 27855–27862.
- Hartl DL, Dykhuizen DE, Dean AM. 1985. Limits of adaptation: the evolution of selective neutrality. *Genetics* 111:655–674.

- Hillenmeyer ME, Fung E, Wildenhain J, et al. (14 co-authors). 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science* 320:362–365.
- Huang X, Liu J, Dickson RC. 2012. Down-regulating sphingolipid synthesis increases yeast lifespan. *PLoS Genet.* 8:e1002493.
- Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD. 2000. Functional discovery via a compendium of expression profiles. *Cell* 102:109–126.
- Huh W-K, Falvo JV, Gerke LC, Carroll AS, Howson RW, Weissman JS, O’Shea EK. 2003. Global analysis of protein localization in budding yeast. *Nature* 425:686–691.
- Khaitovich P, Pääbo S, Weiss G. 2005. Toward a neutral evolutionary model of gene expression. *Genetics* 170:929–939.
- Koybasi S, Senkal CE, Sundararaj K, et al. (12 co-authors). 2004. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. *J Biol Chem.* 279:44311–44319.
- Kvitek DJ, Will JL, Gasch AP. 2008. Variations in stress sensitivity and genomic expression in diverse *S. cerevisiae* isolates. *PLoS Genet.* 4:e1000223.
- Lebman DA, Spiegel S. 2008. Thematic review series: sphingolipids. Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling. *J Lipid Res.* 49:1388–1394.
- Liu H, Styles CA, Fink GR. 1996. *Saccharomyces cerevisiae* S288C has a mutation in FLO8, a gene required for filamentous growth. *Genetics* 144:967–978.
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25:402–408.
- Manolio TA, Collins FS, Cox NJ, et al. (27 co-authors). 2009. Finding the missing heritability of complex diseases. *Nature* 461:747–753.
- McCusker JH, Clemons KV, Stevens DA, Davis RW. 1994. Genetic characterization of pathogenic *Saccharomyces cerevisiae* isolates. *Genetics* 136:1261–1269.
- Mnaimneh S, Davierwala AP, Haynes J, et al. (24 co-authors). 2004. Exploration of essential gene functions via titratable promoter alleles. *Cell* 118:31–44.
- Monaghan E, Gable K, Dunn T. 2002. Mutations in the Lcb2p subunit of serine palmitoyltransferase eliminate the requirement for the TSC3 gene in *Saccharomyces cerevisiae*. *Yeast* 19:659–670.
- Murphy HA, Kuehne HA, Francis CA, Sniegowski PD. 2006. Mate choice assays and mating propensity differences in natural yeast populations. *Biol Lett.* 2:553–556.
- Nagiec MM, Baltisberger JA, Wells GB, Lester RL, Dickson RC. 1994. The LCB2 gene of *Saccharomyces* and the related LCB1 gene encode subunits of serine palmitoyltransferase, the initial enzyme in sphingolipid synthesis. *Proc Natl Acad Sci U S A.* 91:7899–7902.
- Newman JRS, Ghaemmaghami S, Ihmels J, Breslow DK, Noble M, DeRisi JL, Weissman JS. 2006. Single-cell proteomic analysis of *S. cerevisiae* reveals the architecture of biological noise. *Nature* 441:840–846.
- Nijhout HF, Berg AM, Gibson WT. 2003. A mechanistic study of evolvability using the mitogen-activated protein kinase cascade. *Evol Dev.* 5:281–294.
- Orr HA. 1991. A test of Fisher’s theory of dominance. *Proc Natl Acad Sci U S A.* 88:11413–11415.
- Papp B, Pal C, Hurst LD. 2003. Dosage sensitivity and the evolution of gene families in yeast. *Nature* 424:194–197.
- Patton JL, Srinivasan B, Dickson RC, Lester RL. 1992. Phenotypes of sphingolipid-dependent strains of *Saccharomyces cerevisiae*. *J Bacteriol.* 174:7180–7184.
- Patwardhan RP, Lee C, Litvin O, Young DL, Pe’er D, Shendure J. 2009. High-resolution analysis of DNA regulatory elements by synthetic saturation mutagenesis. *Nat Biotechnol.* 27:1173–1175.
- Peng W-T, Robinson MD, Mnaimneh S, Krogan NJ, Cagney G, Morris Q, Davierwala AP, Grigull J, Yang X, Zhang W. 2003. A panoramic view of yeast noncoding RNA processing. *Cell* 113:919–933.
- Perfeito L, Ghazzi S, Berg J, Schnetz K, Lässig M. 2011. Nonlinear fitness landscape of a molecular pathway. *PLoS Genet.* 7:e1002160.
- Rossouw D, Olivares-Hernandes R, Nielsen J, Bauer FF. 2009. Comparative transcriptomic approach to investigate differences in wine yeast physiology and metabolism during fermentation. *Appl Environ Microbiol.* 75:6600–6612.
- Sopko R, Huang D, Preston N, et al. (12 co-authors). 2006. Mapping pathways and phenotypes by systematic gene overexpression. *Mol Cell.* 21:319–330.
- Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB, Brown PO, Botstein D, Futcher B. 1998. Comprehensive identification of cell cycle-regulated genes of the yeast *Saccharomyces cerevisiae* by microarray hybridization. *Mol Biol Cell.* 9:3273.
- Teste M-A, Duquenne M, Francois J, Parrou J-L. 2009. Validation of reference genes for quantitative expression analysis by real-time RT-PCR in *Saccharomyces cerevisiae*. *BMC Mol Biol.* 10:99.
- Tu BP, Kudlicki A, Rowicka M, McKnight SL. 2005. Logic of the yeast metabolic cycle: temporal compartmentalization of cellular processes. *Science* 310:1152–1158.
- Veitia RA. 2002. Exploring the etiology of haploinsufficiency. *BioEssays* 24:175–184.
- Wagner A. 2005. Energy constraints on the evolution of gene expression. *Mol Biol Evol.* 22:1365–1374.
- Wagner A. 2007. Energy costs constrain the evolution of gene expression. *J Exp Zool B Mol Dev Evol.* 308B:322–324.
- Warringer J, Zörgö E, Cubillos FA, et al. (13 co-authors). 2011. Trait variation in yeast is defined by population history. *PLoS Genet.* 7:e1002111.
- Wright KM, Rausher MD. 2010. The evolution of control and distribution of adaptive mutations in a metabolic pathway. *Genetics* 184:483–502.
- Wright S. 1929. Fisher’s theory of dominance. *Am Nat.* 63:274–279.
- Wright S. 1932. The roles of mutation, inbreeding, crossbreeding, and selection in evolution. Proceedings of the 6th International Congress of Genetics, Menasha, WI. Vol. 1. p. 356–366.
- Wright S. 1934. Physiological and evolutionary theories of dominance. *Am Nat.* 68:24–53.
- Yanai I, Hunter CP. 2009. Comparison of diverse developmental transcriptomes reveals that coexpression of gene neighbors is not evolutionarily conserved. *Genome Res.* 19:2214–2220.
- Yasuda S, Nishijima M, Hanada K. 2003. Localization, topology, and function of the LCB1 subunit of serine palmitoyltransferase in mammalian cells. *J Biol Chem.* 278:4176–4183.